These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28463029)

  • 21. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
    Yamaguchi A; Hirata S; Kubo S; Fukuyo S; Hanami K; Nakano K; Nakayamada S; Saito K; Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):799-806. PubMed ID: 31814496
    [No Abstract]   [Full Text] [Related]  

  • 23. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
    Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
    Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.
    Tokai N; Yoshida S; Kotani T; Yoshikawa A; Kimura Y; Fujiki Y; Matsumura Y; Takeuchi T; Makino S; Arawaka S
    PLoS One; 2018; 13(8):e0202601. PubMed ID: 30138480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
    Urata Y; Uesato R; Tanaka D; Nakamura Y; Motomura S
    Ann Rheum Dis; 2012 Apr; 71(4):534-40. PubMed ID: 22021897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.
    Mamehara A; Sugimoto T; Sugiyama D; Morinobu S; Tsuji G; Kawano S; Morinobu A; Kumagai S
    Kobe J Med Sci; 2010 Sep; 56(3):E98-107. PubMed ID: 21063156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
    Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
    Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationship between matrix metalloproteinase-3 levels and articular destructive changes in early and extended rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Karateev DE; Panasyuk EY; Smirnov AV; Cherkasova MV; Nasonov EL
    Ter Arkh; 2016; 88(5):13-18. PubMed ID: 27239921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
    Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
    Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
    Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
    Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis.
    Ammitzbøll CG; Thiel S; Jensenius JC; Ellingsen T; Hørslev-Petersen K; Hetland ML; Junker P; Krogh NS; Østergaard M; Stengaard-Pedersen K
    Arthritis Rheum; 2013 Dec; 65(12):3045-50. PubMed ID: 24022747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
    Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
    Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
    Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
    Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The application of matrix metalloproteinase-3 and 7 joints ultrasonic score in assessment of disease activity in patients with rheumatoid arthritis].
    Zhou L; Song J; Chen L; Xu HJ
    Zhonghua Nei Ke Za Zhi; 2016 Jul; 55(7):531-4. PubMed ID: 27373288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.